Gene-Engineered Immune Cells Achieve Sustained HIV Remission

For the first time, CAR-T cell therapy—a proven cancer treatment—has demonstrated sustained HIV control without lifelong antiretroviral medication, offering tangible proof that training the immune system to suppress the virus is possible. This matters globally because billions lack reliable access to daily HIV medications, making a one-time treatment potentially transformative for public health. Early success in just two patients hints at a future where HIV moves from a chronic illness requiring lifetime treatment to a manageable condition controllable through a single immune cell engineering procedure.